A pooled analysis of the cardiac events in the trastuzumab adjuvant trials
Evandro de Azambuja, Noam Ponde, Marion Procter, Priya Rastogi, Reena S. Cecchini, Matteo Lambertini, Karla Ballman, Alvaro Moreno Aspitia, Dimitrios Zardavas, Lise Roca, Richard D. Gelber, Martine Piccart-Gebhart & Thomas Suter
Breast Cancer Research and Treatment | Volume 170 | Pages 161-171 | January 2020
The addition of the immune therapy drug atezolizumab to chemotherapy after surgery did not provide benefit among patients with triple-negative breast cancer who are at high risk of recurrent disease.
Final 10-year analysis of the ALTTO trial exploring dual anti-HER2 blockade with lapatinib + trastuzumab compared to trastuzumab alone.
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
The consistency of results between the subset of patients from Japan and the global OlympiA population supports the clinical benefit of adjuvant olaparib for patients with gBRCA1/2pv and HER2-negative, high-risk eBC in Japan after completion of local treatment and neoadjuvant or adjuvant CT.
ESMO Open has published an article confirming the cardiac safety of adjuvant anti-HER2 treatment with pertuzumab and trastuzumab.
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer
OlympiA demonstrates statistically significant improvement in overall survival with adjuvant olaparib compared with placebo
Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years’ follow-up
Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
Impact of age on clinical outcomes and efficacy of adjuvant dual anti-HER2 targeted therapy
